• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    5/27/21 5:23:24 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ICPT alert in real time by email
    New Drug Application (NDA): 207999
    Company: INTERCEPT PHARMS INC
    • Email
    • Medication Guide
    • Summary Review

    Products on NDA 207999

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    OCALIVA OBETICHOLIC ACID 5MG TABLET;ORAL Prescription None Yes No
    OCALIVA OBETICHOLIC ACID 10MG TABLET;ORAL Prescription None Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 207999

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    05/27/2016 ORIG-1 Approval Type 1 - New Molecular Entity PRIORITY; Orphan Label (PDF)
    Letter (PDF)
    Review
    Summary Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/207999Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207999Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207999Orig1s000SumR.pdf
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    05/26/2021 SUPPL-7 Labeling-Medication Guide

    Label is not available on this site.

    02/01/2018 SUPPL-3 Labeling-Medication Guide, Labeling-Container/Carton Labels, Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/207999Orig1s003ltr.pdf
    12/21/2016 SUPPL-1 Manufacturing (CMC)

    Label is not available on this site.

    Labels for NDA 207999

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    02/01/2018 SUPPL-3 Labeling-Medication Guide Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf
    02/01/2018 SUPPL-3 Labeling-Container/Carton Labels Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf
    02/01/2018 SUPPL-3 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf
    05/27/2016 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
    Get the next $ICPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICPT

    DatePrice TargetRatingAnalyst
    7/13/2023$8.00 → $19.00Sell → Buy
    H.C. Wainwright
    6/29/2023$12.00 → $18.00Hold → Buy
    Canaccord Genuity
    5/23/2023Buy → Hold
    Needham
    5/22/2023$8.00Neutral → Sell
    H.C. Wainwright
    5/17/2023Outperform → Mkt Perform
    Raymond James
    3/8/2022$31.00 → $29.00Hold
    Canaccord Genuity
    3/3/2022$22.00 → $16.00Sector Perform
    RBC Capital
    3/3/2022$30.00 → $25.00Buy
    Needham
    More analyst ratings